Carotid Endarterectomy versus Carotid Angioplasty Cui Bono  by Moore, W.S.
Eur J Vasc Endovasc Surg (2010) 39, S44eS48Carotid Endarterectomy versus Carotid Angioplasty
Cui Bono*W.S. Moore*Division of Vascular Surgery, David Geffen School of Medicine at UCLA, 200 UCLA Medical Plaza, Room 510-6, Box 956908,
Los Angeles, CA 90095-6908, USA
Submitted 25 August 2009; accepted 6 October 2009






Comparative results* Division of Vascular Surgery, David
UCLA, The Invited Rutherford Lectu
Annual Meeting 3e6 September, 2
Vascular Surgery, Oslo, Norway.
* Tel.: þ1 310 825 9641; fax: þ1 310
E-mail address: wmoore@mednet.
1078-5884/$36 ª 2009 Published by E
doi:10.1016/j.ejvs.2009.10.007Abstract Objectives: To evaluate the current status of carotid angioplasty (CAS) versus
carotid endarterectomy (CEA) in the management of patients with carotid bifurcation disease.
Design: Retrospective review of published and presented prospective randomized trials to
date, regarding comparative results of CAS versus CEA.
Materials: Review of six published prospective randomized trials, one trial presented in press,
and one trial completed and being analyzed. Large population based studies and a comparative
registry study are also included.
Methods: Retrospective literature review.
Results: The results today favor CEA over CAS with respect to stroke morbidity, mortality,
freedom from recurrence, and cost.
Conclusions: At the present time, CEA remains the intervention of choice in the management
of carotid bifurcation disease.
ª 2009 Published by Elsevier Ltd on behalf of European Society for Vascular Surgery.Carotid endarterectomy is a well established intervention
for patients with occlusive disease of the carotid bifurca-
tion. Its efficacy for treatment of both symptomatic1,2 and
asymptomatic3,4 patients has been well documented in
multiple prospective randomized trials. Carotid stent/
angioplasty is a new alternative that is currently undergoing
evaluation. Individual reported experience with stent/
angioplasty as well as prospective registries have shownGeffen School of Medicine at
re, Presented at the XXIII
009, European Society for
794 7648.
ucla.edu
lsevier Ltd on behalf of Europeanstroke morbidity and mortality rates that are competitive
with results reported from NASCET and ACAS. However, it is
a mistake to compare current angioplasty data with 20 year
old carotid endarterectomy data. The results of carotid
endarterectomy have progressively improved over the
intervening time since these early trial results. These
improvements are multifactorial and include better peri-
operative medical management with the use of statins,
beta blockers, ace inhibitors, and anti-platelet agents.
Techniques of carotid endarterectomy have also improved
and, in particular, most surgeons performing carotid
surgery have now had extended training in performing the
operation beyond a basic surgical residency. For these
reasons, the only way to determine the comparative merit
of carotid angioplasty with carotid endarterectomy will beSociety for Vascular Surgery.
CEA vs Carotid Angioplasty e Cui Bono S45in the form of well monitored, properly designed, multi-
institutional prospective randomized trials. Several trials
have already been reported,5e10 and two large trials have
been completed and data are currently under analysis.11,12
The objective of this report is to review the results of
published or reported trials, to examine countrywide data
bases that have been analyzed, and to describe the design
and lead-in data from the CREST trial which will be the
largest trial to date.
Prospective Trials Prior to Anti-Embolism
Protection
The CAVATAS trial
The CAVATAS trial was a multi-institutional study carried
out primarily in the UK. It was begun in 1992. Five hundred
four patients, primarily with symptomatic carotid artery
disease were randomized between angioplasty (CAS) and
carotid endarterectomy (CEA). The results showed no
difference in the 30 day complication rates of death and
stroke, 10% for CAS and 9.9% for CEA.5 Both of these rates
are unacceptably high by current standards and are only of
historical interest. However, the trialists also studied the
incidence of early and late recurrence of stenosis. At one
year, the re-stenosis rate for CAS was 10.5% versus 2.5% for
CEA.13
The Leicester trial
This was meant to be a single institution prospective
randomized trial. The trial was stopped after only 17
patients were randomized for reasons of safety concerns.
Ten patients underwent CEA without death or stroke. Seven
patients underwent CAS with 5 strokes, 3 of which were
disabling.6
The Schneider wall stent trial
This was a multi-institutional prospective randomized trial
that was designed to enter 700 symptomatic patients with
stenoses ranging from 60 to 99%. However, the trial was
stopped by the data and safety monitoring committee after
only 217 patients were randomized. The one-year
combined death and stroke rate for CAS was 12.1% versus
3.6% for CEA. The difference was highly statistically
significant with p< 0.02.7
Prospective Randomized Trials after Anti-
Embolism Protection
The introduction of embolism protection devices was
designed to reduce the incidence of embolic stroke asso-
ciated with balloon angioplasty. Experimental studies have
documented the capture of athero-embolic fragments using
these devices. Interestingly there have been no clinical
studies that demonstrate a stroke risk reduction with the
use of embolic protection devices. Nonetheless it is intui-
tive and it has been taken for granted that they represent
a valuable adjunct.The Sapphire trial
Stenting and Angioplasty with Protection in Patients at High-
Risk for Endarterectomy (SAPPHIRE) was a trial with 3 arms.
There was a registry for CAS and a registry for CEA in patients
who did not wish to be randomized and a prospective
randomized trial for those who were willing to be random-
ized. The Angioguard filter and Precise stentwere used in the
CAS arms of the trial. The two registries are of minimal
interest. The randomized trial consisted of only 307 patients
with either symptomatic carotid stenosis >50% or asymp-
tomatic patientswith stenoses>80%.High riskwasdefinedas
a patient with multiple medical co-morbidities or difficult
surgical access such as a radiated neck, prior carotid surgery,
a high lesion, tracheotomy, etc. The traditional endpoints of
stroke and death were included, but for the first time in
a carotid trial, myocardial infarction was added as a primary
endpoint. Furthermore, non-Q wave myocardial infarction
received equal weight as an endpoint. Of the total of 307
patients, 156 underwent CAS and 151 underwent CEA. There
was no difference in the combined endpoints of death and
stroke, 4.5% for CAS and 6.6% for CEA. However, when
myocardial infarction was added to death and stroke, the
combined endpoints reached a statistically significant
difference favoring CAS. The combined endpoints were 5.8%
for CAS and 12.6% for CEA at the end of 30 days.8 These
differences held for 1 year, but by four years, there was no
difference between the two groups when considering
freedom from stroke, freedom from death, and freedom
from major adverse events.14 There have been several crit-
icisms of this study which include a small sample size and
providingequal endpoint valueof non-QwaveMI todeathand
stroke.The EVA 3S study (endarterectomy versus angioplasty in
patients with severe symptomatic carotid stenosis)
The EVA 3S study was a large multi-institutional prospective
randomized trial carried out in France. Symptomatic
patients with hemodynamically significant carotid stenosis
were randomly allocated to CAS or CEA. After 527 patients
were randomized, the study was stopped by the data and
safety monitoring committee. The combined death and
stroke rate for CEA was 3.9% whereas the rate for CAS was
9.6%. These differences were statistically significant and
clearly favored CEA as the safer procedure.9 The EVA 3S
investigators also reported their data after 4 years. The
four year ipsilateral stroke rate was 11.1% in CAS versus
6.2% in CEA. The combined four year death and stroke rate
was 26.9% in CAS versus 21.6% in CEA, once again favoring
CEA over CAS after four years of follow-up.15 This study was
criticized by the interventional community in the United
States who implied that those who did the CAS procedure
were not sufficiently experienced and that this led to
a higher complication rate. In a post-hoc analysis, the
authors separated out the ‘‘high volume’’ interventionists
from those with lower volume experience in order to
compare their results. There was no difference between
the two groups performing CAS.
The SPACE (Stent-Supported Percutaneous Angioplasty
of the Carotid Artery Versus Endarterectomy) Trial. This
was a multi-institutional prospective randomized trial
Table 1 Recent trial comparative data CEA versus CAS.





Sapphire High Symptomatic 10.3% 2.1% NS
Sapphire High Asymptomatic 6.1% 5.2% NS
EVA-3S Average Symptomatic 3.9% 9.6% 0.01
Space Average Symptomatic 6.5% 7.7% NS
ICSS Average Symptomatic 5.1% incl. MI 8.5% incl. MI 0.004
S46 W.S. Moorecarried out in Germany, Austria, and Switzerland in which
symptomatic patients with high grade carotid stenosis were
randomly allocated to either CAS or CEA. The hypothesis of
the trial was that CAS was not inferior to CEA and the
statistical analysis was applied accordingly. The trial was
stopped prematurely because a futility analysis revealed
that further addition of patients was unlikely to reach an
endpoint. At the time the trial was stopped, the 30 day
death and stroke rate for CAS was 7.7% and 6.5% for CEA.
The conclusion was that the trial failed to prove that CAS
was not inferior to CEA.10 The trialists also reported upon
the 2 year incidence of recurrent stenosis >70%. The inci-
dence following CAS was 10.7% versus 4.6% after CEA.16
The International Carotid Stenting Study (ICSS)
The ICSS study and results were presented at the European
Stroke Conference held in Stockholm, Sweden on May 28th,
2009. The study involved 50 centers in 15 countries. The
report has not yet been published. This is the largest trial
reported to date. Seventeen hundred and ten patients with
symptomatic, high grade carotid stenoses were randomly
allocated to either CAS or CEA. Eight hundred fifty three
patients underwent CAS and 857 patients underwent CEA.
The endpoints included stroke, MI, and death within 30
days. In an intension to treat analysis, the incidence was
8.5% in the CAS group versus 5.1% in the CEA group
(pZ 0.004). When the results were subjected to a per
protocol analysis, the incidence was 7.4% in the CAS group
and 4% in the CEA group (pZ 0.003).11
These results, when confirmed by peer review, clearly
will favor CEA as the procedure of choice for symptomatic
patients with high grade carotid stenosis. The recent
randomized trial data are summarized in Table 1.
The CREST (carotid revascularization
endarterectomy versus stenting) trial
The patient input was completed one year ago and the one
year data are currently being analyzed. When reported,Table 2 Population based studies.
Trial Risk category Symptomatic status
NIS 2003/4 All Asymptomatic
NIS 2003/4 All Symptomatic
SVS registry All Symptomatic
SVS registry All Asymptomaticthis will be the largest trial to date. Two thousand five
hundred and two patients (1321 symptomatic and 1181
asymptomatic) were randomly allocated to either pro-
tected balloon angioplasty and stenting or carotid endar-
terectomy. The design of this trial has several unique
features. In recognition of the fact that the majority of
patients undergoing CEA are asymptomatic, this study
includes both symptomatic and asymptomatic patients. It is
also stratified to be able identify any result differences
related to gender. Finally, in order to address the issue
regarding competence of those performing CAS, the inter-
ventional management committee first screened potential
participants regarding angioplasty experience. Those who
qualified after the initial review were required to
prospectively submit up to 20 CAS patients that followed
the CREST protocol and were subject to the same endpoint
analysis. If the prospective participant demonstrated
competence in this manner, then and only then, were they
permitted to participate in randomization. Surgeons who
wished to participate were screened by a surgical
management committee using the criteria validated in the
ACAS study.12,17,18 CREST has received permission from the
data and safety monitoring committee to report one year
results. That analysis is currently underway and publication
is anticipated in early 2010. In the meantime, data from the
lead in phase of CREST have been reported regarding
the results of CAS prior to randomization. First of all, the
overall 30 day death, stroke, and MI rate in patients
undergoing CAS was 5.1%. For asymptomatic patients, the
rate was 4.9% and for symptomatic patients, the rate was
5.8%.19 In addition, advancing age has an exponentially
adverse effect on CAS complications. At 30 days, the death,
stroke, and MI rate for CAS in patients less than 60 years of
age was 2.2%, for patients 60e69, it was 2.5%, for patients
70e79, it jumps to 6.4%, and for patients over the age of
80, it jumps again to 13.9%.20 It was also noted that
bleeding complications associated with CAS had an adverse
outcome following CAS. The incidence of hemorrhagic





1.22% 2.24% p< 0.0001
2.16% 11.7% p< 0.001
3.75% incl. MI 7.13% incl. MI 0.014
1.97% 4.6% incl. MI 0.003
CEA vs Carotid Angioplasty e Cui Bono S477.3%. The death and stroke rate following CAS if there was
a hemorrhagic complication was 19.6% versus 4.4% in the
absence of hemorrhagic complications. In follow-up, the
one year re-stenosis rate was monitored. At one year, 28%
of CAS patients had a re-stenosis greater than 50%. Seven
percent had a re-stenosis in the severe 80e99% category,
and 0.3% had a total occlusion.
Population Based Studies
United States hospital discharge statistics 2003e
2004
The NIS data base was sampled for the incidence of CEA and
CAS as well as the complication rates of stroke and death
for the years 2003 and 2004. There was a total of 259,080
patients undergoing carotid revascularization during that
two-year interval. 245,045 (94.6%) underwent CEA and
14,035 (5.4%) underwent CAS. Ninety-two percent of the
patients were asymptomatic and eight percent were
symptomatic. The overall death and stroke rate for CAS was
3.4% whereas the overall death and stroke rate for CEA was
1.17%. The death and stroke rate in asymptomatic patients
undergoing CAS was 2.24% versus 1.22% for CEA. In symp-
tomatic patients, the death and stroke rate for CAS was
11.7% versus 2.16% for CEA.21
The SVS registry
Most registry data are industry supported and tend to be
self serving. However CMS, the organization responsible for
administering Medicare and Medicaid in the United States
has mandated that all hospitals who wish to perform CAS
must submit their data to an approved registry in order to
track communitywide results. The Society for Vascular
Surgery (SVS) has established an approved registry to which
hospitals can submit their data. In addition, the SVS registry
went one step further. They required that any hospital that
wished to use their registry for submission of CAS results
must also submit their CEA data. Thus the SVS data base
provides the opportunity to compare the results of CAS with
CEA from the same hospital pool. In their initial report, the
SVS registry had 645 symptomatic patients who underwent
CAS with a 30 day combined death, stroke, and MI rate of
7.13%. At the same time, 506 symptomatic patients
underwent CEA with a combined death, stroke, and MI rate
of 3.75% (pZ 0.014). The registry also reported data on 805
asymptomatic patients undergoing CAS with a combined
death, stroke, and MI rate of 4.6% versus 606 asymptomatic
patients undergoing CEA with a combined death, stroke,
and MI rate of 1.97% (pZ 0.003).22 The population based
studies are summarized in Table 2.Cost Analysis
In these days of escalating health care costs, the compar-
ative cost of competing interventions, as well as compar-
ative results, must be taken into consideration. The
national hospital discharge data base for the year 2005
provides some insight into this issue. The average hospitalcharge for CEA in asymptomatic patients was $27,000. The
average hospital charge for CAS in asymptomatic patients
was $32,400. The average hospital charge for CEA in
symptomatic patients was $37,000. The average hospital
charge for CAS in symptomatic patients was $63,000.23
Conclusions
Based upon the current prospective randomized trial data
and clinical utilization results, one must conclude that CAS
carries a higher morbidity/mortality at a higher dollar cost
than CEA. The results of CREST, when available, may
change that conclusion. In the meantime, when asked cui
bono (who benefits), one must conclude that the benefi-
ciaries of CAS are the device manufacturers and interven-
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